CTOs on the Move


 
At AbbVie, we believe the world needs new approaches to addressing today`s health issues — from life-threatening illness to chronic conditions. We combine advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people`s lives. With 28,000+ employees and medicines in over 170 countries, AbbVie is uniting the best of pharma and the boldness of biotech, to innovate end-to-end approaches that make a real difference in people`s lives.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.abbvie.com
  • 1 North Waukegan Road
    North Chicago, IL USA 60064
  • Phone: 847.932.7900

Executives

Name Title Contact Details
Shannon Sword
Director of Information Security Profile
Ryan Hillsberg
Head of U.S. Operations Global Security Profile
Kyle Egloff
Director, Business Technology Solutions Profile
Mark Johnson
Associate Director, Information Security Profile
Steven Walters
Associate Director, Business Information Security Profile

Similar Companies

Slayback Pharma

Slayback Pharma LLC is a specialty pharmaceutical company focused on developing, manufacturing and sourcing of complex generic pharmaceutical products, with a specific emphasis on complex injectables and other non-solid oral products. Slayback has created a unique portfolio of complex generics by smart product selection and execution and connecting various dots through a network of contract R&D laboratories and manufacturing organizations, comprising smart and rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies.

InnerScope Hearing Technologies

Homepage for InnerScope Hearing Technologies, a hearing care company who sells Direct-to-Consumer Hearing Aids.

San Antonio Behavioral Healthcare Hospital

San Antonio Behavioral Healthcare Hospital is a trusted mental health treatment facility location in San Antonio, TX

Karyopharm

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm`s SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm`s lead compound, XPOVIO™ (selinexor), received accelerated approval from the FDA in July 2019 in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.

Afexa Life Sciences

Afexa Life Sciences Inc. is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.